Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MediciNova, Inc. (MNOV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2100-0.0100 (-0.45%)
At close: 04:00PM EST
2.1800 -0.03 (-1.36%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2200
Open2.1500
Bid2.2000 x 1800
Ask2.4500 x 2200
Day's Range2.1300 - 2.2500
52 Week Range2.1300 - 10.8100
Volume120,330
Avg. Volume529,791
Market Cap108.385M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.2320
Earnings DateFeb 16, 2022 - Feb 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

    LA JOLLA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the patent ma

  • GlobeNewswire

    MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

    LA JOLLA, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND (amyotrophic lateral sclerosis/mo

  • Zacks Small Cap Research

    MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model…

    By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 in Combination with PD-1 Inhibitor Extends Survival in Preclinical Model On November 22, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced results from a preclinical study of MN-166 (ibudilast) in combination with a PD-1 inhibitor presented at the 26 th Annual Meeting of the Society for Neuro-Oncology (SNO).

Advertisement
Advertisement